순환종양세포(CTC) 및 암 줄기세포(CSC) 시장 보고서 : 동향, 예측, 경쟁 분석(-2035년)

Circulating Tumor Cell and Cancer Stem Cell Market

The future of the global circulating tumor cell and cancer stem cell market looks promising with opportunities in the hospital, diagnostic laboratory, and research institute markets. The global circulating tumor cell and cancer stem cell market is expected to reach an estimated $15.1 billion by 2035 from $7.7 billion in 2027 with a CAGR of 11.5% from 2027 to 2035. The major drivers for this market are the increasing prevalence of cancer cases, the rising demand for early cancer detection, and the growing focus on personalized cancer treatments.

• Lucintel forecasts that, within the cancer type category, breast cancer is expected to witness the highest growth over the forecast period due to increasing breast cancer cases motivates the development of liquid biopsies.
• Within the end use category, hospitals is expected to witness the highest growth over the forecast period due to increasing adoption of advanced cancer diagnostic tests within hospitals.
• In terms of regions, North America is expected to witness the highest growth over the forecast period due to robust cancer research and diagnostic infrastructure.

Emerging Trends in Circulating Tumor Cell and Cancer Stem Cell Market

The time period from 2025 to 2027 is anticipated to see further development of circulating tumour cell (CTC) and cancer stem cell (CSC) analysis methods in the field of liquid biopsies. Easier methods of profiling tumour cells and more advanced single-cell analyses are facilitating the design and implementation of oncology clinical trials. When providing the market update, Lucintel should touch upon evidence, reimbursement and integration with the line of treatment.

• Clinical Validation: Increasingly, from 2025 onwards, studies are evaluating the role of CTCs and CSCs to assess response and relapse as well as minimal residual disease. Further, in an effort to assess the efficacy of a treatment, studies are evaluating tumour markers in blood prior to, during and after the administration of the treatment.
• Single Cell Analysis: The field of single-cell analysis is rapidly advancing. From 2025, oncology studies are anticipated to evaluate thousands of single cells per sample and assess tumour cell populations that are resistant to treatment.
• Improved Automation: Reproducibility of tests is expected to improve with the introduction of more automated platforms. Between 2025 and 2027, larger and more advanced automated instruments are expected, which integrate the entire process from capture and counting to digital reporting.
• Integration with Liquid Biopsy: Cancer Stem Cells (CSCs) and Cancer T cells (CTCs) will be integrated in longer and more complex liquid biopsy panels, including other Circulating Tumour components (DNA, RNA, and Proteins). Between 2025 and 2027, more advanced and integrated liquid biopsy panels will facilitate longitudinal monitoring. The integration of liquid biopsy panels will facilitate the use of biopsy in routine clinical practice.
• New Alliances: Companies engaged in the development of oncology drugs and oncology diagnostics are collaborating to evaluate the role of CTCs and CSCs in clinical trials, especially to understand metastatic disease and/or tumour cell/cells resistance. Sampling will be performed at multiple time points and/or throughout treatment, as opposed to the traditional sampling at the time of disease progression.

The focus for CTC and CSC assays will be on developing companion diagnostics and oncology monitoring. Between 2025 and 2027, these assays will become more integrated with other oncology liquid biopsy and diagnostic platforms.

Recent Developments in the Circulating Tumor Cell and Cancer Stem Cell Market

The market for circulating tumour cells and cancer stem cells is shifting from preliminary research to clinical, evaluable tests. This shift began in 2025 with improvements in liquid biopsy, as well as the alignment of Pharma companion diagnostic projects, and modular changes in the regulations concerning IVDs. Although we are seeing growth in the oncology monitoring market, reimbursement is still stagnant.

• Clinical Validation: The FDA's approval of Guardant Health's liquid biopsy, Shield, in 2024, set a regulatory framework for liquid biopsies. In 2025, other CTC and cancer stem cell assays launched clinical studies to assess their impact on patient outcomes. These studies are expected to positively influence the reimbursement status of these assays.
• Platform Partnerships: In 2025, collaborations between Menarini Silicon Biosystems and research hospitals, to standardize CTC enumeration in clinical studies of metastatic cancers, continued. These collaborations provide clinical research institutions the opportunity to develop and commercialize recurring cancer tests.
• New Technologies: In 2025, RareCyte, a start-up focused on multiplexing circulating and tumour cells, released its first products. These products incorporated imaging and protein identification and should facilitate the development of assays for evaluating the efficacy of new oncology drugs.
• Pharma Contracts: The number of contracts by biopharma sponsors for the use of cancer stem cell and CTC assays in oncology trials 2025 (and beyond) has increased. The increase is for the monitoring of response and the study of resistance. It is expected that these contracts will increase to the extent that these services will be part of the standard services offered by clinical trial units, and no longer be restricted to specialist services.
• Government: The 2025 funding (of the EU Cancer Mission) supported research on the use of liquid biopsies for cancer. Public funding of biomedical innovations will facilitate smaller companies to gain evidence on the value of their products (for licensing and acquisition).

Not all technologies will find a place in the clinical domain, but those that do, are expected to dominate in the field in the coming years. The demand for CTC enumeration and characterization is expected to rise. The same is expected for the use of cancer stem cells for research in the pharmaceutical industry and certain academic institutions.

Strategic Growth Opportunities in the Circulating Tumor Cell and Cancer Stem Cell Market

Demand for circulating tumour cells (CTCs) and cancer stem cells (CSCs) is expected to increase during the years 2024-2026, as the field of oncology focuses more on the early detection of cancers, selection of oncologic therapies, and the monitoring of cancerous reoccurrences. According to Lucintel, the establishment of the commercial

laboratory industry for liquid-biopsies and the investment of the pharmaceutical industry for development of anti-cancer therapies will promote the progress in the field of precision oncology.

• Companion Diagnostics: CTC and CSC assays can help select anti-cancer therapies and help in the monitoring of resistance to such therapies. FDA approved in January 2025, more than 170 oncologic companion diagnostics. It is expected that during the next 5 years, the pharmaceutical industry will help fund the development of cellular biomarkers to help accelerate clinical trials and help in selection of personalized anti-cancer therapies.
• Minimal Residual Disease (MRD): Testing for the presence of cancer cells after surgical removal of a primary tumour is expected to help health care professionals identify cancers at earlier stages. The National Cancer Institute in February 2025 listed more than 1000 ongoing cancer-related clinical trials evaluating MRD.
• Pharmaceutical Biomarker Services: The biopharmaceutical industry is interested in integrating CTC and CSC assays in clinical trials to validate surrogate endpoints. With over 500,000 trials listed on ClinicalTrials.gov in March 2025, the potential outsourcing opportunities is significantly large and growing. Laboratories can process samples, sequence the DNA, and perform longitudinal studies, as a recurring service.
• Single-cell Precision Oncology: Cell capture and genomic/ transcriptomic analysis can help discover resistant cell populations. The Human Cell Atlas in April 2025, document cell types across more than 50 million cells. Innovations in these areas will not only catalyse service offerings but also instrument and compound sales.
• Oncology in Emerging Markets: There is untapped demand for these services in Asia-Pacific, Latin America and the Middle East. According to the World Health Organization, in 2022, more than 9.94 million people lost their lives due to cancer. Affordable and strategic partnerships will help these services reach customers.

There is sufficient proof of clinical value for several applications to warrant the commercialization of these offerings. Additionally, the ability to consistently capture cells along with long term contracts will help offset the cost of the equipment. Companies that provide these services will have an advantage over the competition. Routinary tests will gain commercial value before other offerings.

Circulating Tumor Cell and Cancer Stem Cell Market Drivers and Challenges

The markets for circulating tumour cells and cancer stem cells are set to grow due to a variety of social, economic and political reasons. New techniques in single cell analysis and oncology coupled with advances in liquid biopsy increase the range of oncology tests available. Meanwhile, traditional barriers such as the economics of healthcare and reimbursement slow the pace of adoption. According to Lucintel, the rise of innovative cancer screening and the removal of regional barriers will promote growth in this sector.

The factors responsible for driving this market include:

• Increased Use of Liquid Biopsy: More acceptable and less invasive methods of cancer monitoring and analysis are fueling the use of CTC and CSC assays. Several studies published in March 2025 used blood samples to monitor cancer and help choose the best treatment. As the use of blood sample biopsies become more prevalent and easier, it is expected that tests to monitor cancer and help in the development of new oncology drug and clinical trials will also increase.
• Improvements in Single-cell Technology: Microfluidics, imaging, and sequencing have improved the identification and analysis of tumour cells. In June 2025, single cell oncology workflows enabled analysis of genomic and transcriptomic characteristics in a single assay. Single cell analyses facilitate the understanding of tumour cell populations and the classification of tumour cells. This is likely to establish the basis of the market and advance the field of oncology.
• Increased Demand for Precision Oncology: Healthcare providers are focused on understanding how tumors spread, the risk of tumour progression, and the efficacy of tumour therapies. In September 2025, a premium was placed on the continuous evaluation of tumour cell characteristics and heterogeneity. C tumour cell and cancer stem cell assays are additional means of evaluating tumour characteristics and are likely to gain popularity.
• Drug Development and Oncology: Metastasis and the development of tumour cell resistance to therapies remain challenges in the field of oncology. Increased use of circulating tumour cells and cancer stem cells in drug development is aimed at overcoming these challenges. The increased focus on personalized medicine is expected to propel the market and advance the field of oncology.
• Cancer Burden and Screening Investment: Cancer cases are rising, as is funding for cancer screening. This creates a need for technology that tracks the status of a patient's cancer. April 2026 was the latest date for which information was available for this report, and at that time, international organizations focused on cancer continued efforts to speed up the diagnosis of cancer and improve the molecular monitoring of cancer. There are opportunities in the next 3 to 5 years for improvement in the cancer infrastructure of different countries. During this time, awareness of and access to continuous personalized cancer care will increase. The same will be true for the access to and use of special laboratories. During this time, there will be a greater ability to monitor cancer through the use of special cells.

The challenges facing this market include:

• Limited Clinical Standardization: Cell preparation and enrichment methods, markers, and reporting all vary from lab to lab. Inconsistent results create delays in the development of clinical practice guidelines and affect reimbursement. In 2025, there were many Advanced Oncology Testing services provided outside the scope of insurance. For the next 3 to 5 years, similar situations are expected to occur in the areas where cancer care is still developing. To change this, standards need to be developed and (stricter) quality assurance controls need to be implemented. Large-scale integrated studies also need to be performed.
• Barriers To Reimbursement: Costly and complex Cancer Biomarker tests lead to long turnaround times. In 2025, many of the advanced Oncology testing services were being funded by patients or performed as research. For the next 3 to 5 years, the same situation will occur in underdeveloped countries. Manufacturers need to reduce costs and improve the overall value of their products.
• Biological and Regulatory Complexity: Circulating tumour cells (CTCs) are rare, heterogeneous, and biologically labile. Cancer stem cells (CSCs) are currently defined functionally, and are marked phenotypically. Identification of CSCs varies by tumour type and grade. The assessment of CTC and CSC tests continued in 2026, focusing on analytical validation and clinical use. Reproducibility remained a challenge. It is expected that the expanding oncology diagnostic market will have a positive effect on CTC and CSC tests; however, the long and arduous nature of traditional clinical trial pathways inhibits market growth. The onus is on test developers to establish clinical value and impact.

The field of CTC and CSC analysis is progressing due to demand for innovations in oncology. Availability of new diagnostic and therapeutic pharmacologic agents coupled with advances in bioinformatics, omics and other assay and analytics technologies will accelerate the adoption of CTC/CSC assays. The ability to integrate new technologies with routine diagnostics will be governed by the pace of regulation and automation.

List of Circulating Tumor Cell and Cancer Stem Cell Market Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies circulating tumor cell and cancer stem cell market companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the circulating tumor cell and cancer stem cell market companies profiled in this report include-

• ApoCell Inc.
• Biocept Inc.
• CellTraffix Inc.
• Clearbridge BioMedics Pte Ltd.
• Epic Sciences Inc.
• Fluxion Biosciences Inc.
• Greiner Bio-One International GmbH
• Ikonisys Inc.
• IVDiagnostics Inc.
• Janssen Diagnostics LLC

Circulating Tumor Cell and Cancer Stem Cell Market by Segment

The study includes a forecast for the global circulating tumor cell and cancer stem cell market by cancer type, technology, application, end use, and region.

Circulating Tumor Cell and Cancer Stem Cell Market by Cancer Type [Value ($B) from 2019 to 2035]:

• Breast Cancer
• Prostate Cancer
• Colorectal Cancer
• Lung Cancer
• Others

Circulating Tumor Cell and Cancer Stem Cell Market by Technology [Value ($B) from 2019 to 2035]:

• CTC Enrichment
• CTC Detection
• CTC Analysis
• CSC Identification
• CSC Isolation
• CSC Characterization

Circulating Tumor Cell and Cancer Stem Cell Market by Application [Value ($B) from 2019 to 2035]:

• Clinical Diagnostics
• Research & Development
• Liquid Biopsy
• Prognosis
• Therapy Selection
• Others

Circulating Tumor Cell and Cancer Stem Cell Market by End Use [Value ($B) from 2019 to 2035]:

• Hospitals
• Diagnostic Laboratories
• Research Institutes
• Others

Circulating Tumor Cell and Cancer Stem Cell Market by Region [Value ($B) from 2019 to 2035]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Circulating Tumor Cell and Cancer Stem Cell Market

The market for circulating tumour cells and cancer stem cells is shifting from research-based tests to clinical-based, liquid biopsy, and single cell analysis. The next few years will see collaboration and partnerships among public oncology, regulatory and other stakeholders to determine commercial policies. Based on the latest report by Lucintel, the primary consideration for purchasing these platforms is whether they have been medically validated.

• United States: The Food and Drug Administration's (FDA) approval of Guardant Health's Shield test in July 2024 created a pathway for other blood-based cancer testing and increased market confidence in this type of testing. The National Cancer Institute's (NCI) Cancer Screening Research Network has initiated multiple large-scale clinical trials to validate cancer screening and further establish its reimbursement.
• China: China's 13th Five-Year Plan for Cancer Control and Prevention (2023-2027) aims to improve the standardization and increase the accessibility of cancer screening and diagnostics. Concurrently, the Chinese Centre for Disease Control and Prevention (CDC) has implemented several nationwide cancer screening programs for high prevalence cancers. This increased focus by the Chinese government will increase the availability of CTC testing and other oncology diagnostics.
• Germany: The German Cancer Research Centre invested in Heidelberg-based liquid biopsy and single-cell research in 2025. German collaborations focused on genomic and cellular integrations. These initiatives enhance Germany's opportunity to engage in CTC and cancer stem cell testing and/or research.
• India: Cancer research supported by the Department of Biotechnology (DBT) and Indian Council of Medical Research (ICMR) is integrated and growing. ICMR's National Cancer Registry Programme has developed and established 60 plus population and/or hospital-based cancer registries. These registries have the potential to facilitate the development of CTC and/or cancer stem cell technology and foster the generation of clinical data to support it, in India.
• Japan: Funded by the AMED, liquid biopsy and other precision oncology initiatives are ongoing. The Pharmaceuticals and Medical Devices Agency of Japan foster pathways for companion diagnostics and other complex laboratory testing. Continued public interest and the aging population of Japan is expected to stimulate the development of various minimally invasive medical diagnostic technologies.

Features of the Global Circulating Tumor Cell and Cancer Stem Cell Market

• Market Size Estimates: circulating tumor cell and cancer stem cell market size estimation in terms of value ($B).
• Trend and Forecast Analysis: Market trends (2019 to 2026) and forecast (2027 to 2035) by various segments and regions.
• Segmentation Analysis: circulating tumor cell and cancer stem cell market size by various segments, such as by cancer type, technology, application, end use, and region in terms of value ($B).
• Regional Analysis: circulating tumor cell and cancer stem cell market breakdown by North America, Europe, Asia Pacific, and Rest of the World.
• Growth Opportunities: Analysis of growth opportunities in different cancer types, technologies, applications, end uses, and regions for the circulating tumor cell and cancer stem cell market.
• Strategic Analysis: This includes M&A, new product development, and competitive landscape of the circulating tumor cell and cancer stem cell market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the circulating tumor cell and cancer stem cell market by cancer type (breast cancer, prostate cancer, colorectal cancer, lung cancer, and others), technology (CTC enrichment, CTC detection, CTC analysis, CSC identification, CSC isolation, and CSC characterization), application (clinical diagnostics, research & development, liquid biopsy, prognosis, therapy selection, and others), end use (hospitals, diagnostic laboratories, research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 8 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Market Overview

• 2.1 Background and Classifications
• 2.2 Supply Chain

3. Market Trends & Forecast Analysis

• 3.1 Macroeconomic Trends and Forecasts
• 3.2 Industry Drivers and Challenges
• 3.3 PESTLE Analysis
• 3.4 Patent Analysis
• 3.5 Regulatory Environment

4. Global Circulating Tumor Cell and Cancer Stem Cell Market by Cancer Type

• 4.1 Overview
• 4.2 Attractiveness Analysis by Cancer Type
• 4.3 Breast Cancer : Trends and Forecast 2019 to 2035
• 4.4 Prostate Cancer : Trends and Forecast 2019 to 2035
• 4.5 Colorectal Cancer : Trends and Forecast 2019 to 2035
• 4.6 Lung Cancer : Trends and Forecast 2019 to 2035
• 4.7 Others : Trends and Forecast 2019 to 2035

5. Global Circulating Tumor Cell and Cancer Stem Cell Market by Technology

• 5.1 Overview
• 5.2 Attractiveness Analysis by Technology
• 5.3 CTC Enrichment : Trends and Forecast 2019 to 2035
• 5.4 CTC Detection : Trends and Forecast 2019 to 2035
• 5.5 CTC Analysis : Trends and Forecast 2019 to 2035
• 5.6 CSC Identification : Trends and Forecast 2019 to 2035
• 5.7 CSC Isolation : Trends and Forecast 2019 to 2035
• 5.8 CSC Characterization : Trends and Forecast 2019 to 2035

6. Global Circulating Tumor Cell and Cancer Stem Cell Market by Application

• 6.1 Overview
• 6.2 Attractiveness Analysis by Application
• 6.3 Clinical Diagnostics : Trends and Forecast 2019 to 2035
• 6.4 Research & Development : Trends and Forecast 2019 to 2035
• 6.5 Liquid Biopsy : Trends and Forecast 2019 to 2035
• 6.6 Prognosis : Trends and Forecast 2019 to 2035
• 6.7 Therapy Selection : Trends and Forecast 2019 to 2035
• 6.8 Others : Trends and Forecast 2019 to 2035

7. Global Circulating Tumor Cell and Cancer Stem Cell Market by End Use

• 7.1 Overview
• 7.2 Attractiveness Analysis by End Use
• 7.3 Hospitals : Trends and Forecast 2019 to 2035
• 7.4 Diagnostic Laboratories : Trends and Forecast 2019 to 2035
• 7.5 Research Institutes : Trends and Forecast 2019 to 2035
• 7.6 Others : Trends and Forecast 2019 to 2035

8. Regional Analysis

• 8.1 Overview
• 8.2 Global Circulating Tumor Cell and Cancer Stem Cell Market by Region

9. North American Circulating Tumor Cell and Cancer Stem Cell Market

• 9.1 Overview
• 9.2 North American Circulating Tumor Cell and Cancer Stem Cell Market by Cancer Type
• 9.3 North American Circulating Tumor Cell and Cancer Stem Cell Market by End Use
• 9.4 The United States Circulating Tumor Cell and Cancer Stem Cell Market
• 9.5 Canadian Circulating Tumor Cell and Cancer Stem Cell Market
• 9.6 Mexican Circulating Tumor Cell and Cancer Stem Cell Market

10. European Circulating Tumor Cell and Cancer Stem Cell Market

• 10.1 Overview
• 10.2 European Circulating Tumor Cell and Cancer Stem Cell Market by Cancer Type
• 10.3 European Circulating Tumor Cell and Cancer Stem Cell Market by End Use
• 10.4 German Circulating Tumor Cell and Cancer Stem Cell Market
• 10.5 French Circulating Tumor Cell and Cancer Stem Cell Market
• 10.6 Italian Circulating Tumor Cell and Cancer Stem Cell Market
• 10.7 Spanish Circulating Tumor Cell and Cancer Stem Cell Market
• 10.8 The United Kingdom Circulating Tumor Cell and Cancer Stem Cell Market

11. APAC Circulating Tumor Cell and Cancer Stem Cell Market

• 11.1 Overview
• 11.2 APAC Circulating Tumor Cell and Cancer Stem Cell Market by Cancer Type
• 11.3 APAC Circulating Tumor Cell and Cancer Stem Cell Market by End Use
• 11.4 Chinese Circulating Tumor Cell and Cancer Stem Cell Market
• 11.5 Indian Circulating Tumor Cell and Cancer Stem Cell Market
• 11.6 Japanese Circulating Tumor Cell and Cancer Stem Cell Market
• 11.7 South Korean Circulating Tumor Cell and Cancer Stem Cell Market
• 11.8 Indonesian Circulating Tumor Cell and Cancer Stem Cell Market

12. ROW Circulating Tumor Cell and Cancer Stem Cell Market

• 12.1 Overview
• 12.2 ROW Circulating Tumor Cell and Cancer Stem Cell Market by Cancer Type
• 12.3 ROW Circulating Tumor Cell and Cancer Stem Cell Market by End Use
• 12.4 Middle Eastern Circulating Tumor Cell and Cancer Stem Cell Market
• 12.5 South American Circulating Tumor Cell and Cancer Stem Cell Market
• 12.6 African Circulating Tumor Cell and Cancer Stem Cell Market

13. Competitor Analysis

• 13.1 Product Portfolio Analysis
• 13.2 Operational Integration
• 13.3 Porter's Five Forces Analysis
  • Competitive Rivalry
  • Bargaining Power of Buyers
  • Bargaining Power of Suppliers
  • Threat of Substitutes
  • Threat of New Entrants
• 13.4 Market Share Analysis

14. Opportunities & Strategic Analysis

• 14.1 Value Chain Analysis
• 14.2 Growth Opportunity Analysis
  • 14.2.1 Growth Opportunity by Cancer Type
  • 14.2.2 Growth Opportunity by Technology
  • 14.2.3 Growth Opportunity by Application
  • 14.2.4 Growth Opportunity by End Use
• 14.3 Emerging Trends in the Global Circulating Tumor Cell and Cancer Stem Cell Market
• 14.4 Strategic Analysis
  • 14.4.1 New Product Development
  • 14.4.2 Certification and Licensing
  • 14.4.3 Mergers, Acquisitions, Agreements, Collaborations, and Joint Ventures

15. Company Profiles of the Leading Players Across the Value Chain

• 15.1 Competitive Analysis Overview
• 15.2 ApoCell Inc.
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.3 Biocept Inc.
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.4 CellTraffix Inc.
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.5 Clearbridge BioMedics Pte Ltd.
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.6 Epic Sciences Inc.
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.7 Fluxion Biosciences Inc.
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.8 Greiner Bio-One International GmbH
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.9 Ikonisys Inc.
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.10 IVDiagnostics Inc.
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing
• 15.11 Janssen Diagnostics LLC
  • Company Overview
  • Circulating Tumor Cell and Cancer Stem Cell Market Business Overview
  • New Product Development
  • Merger, Acquisition, and Collaboration
  • Certification and Licensing

16. Appendix

• 16.1 List of Figures
• 16.2 List of Tables
• 16.3 Research Methodology
• 16.4 Disclaimer
• 16.5 Copyright
• 16.6 Abbreviations and Technical Units
• 16.7 About Us
• 16.8 Contact Us